Pulmotect, Inc.
  • Home
  • About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Overview
    • Our Science
    • Our Pipeline
    • Published Journal Articles
  • News
  • Contact Us

Houston biotech company receives $3 million

Posted on May 1, 2015April 1, 2017 by admin
Posted in News Coverage

Post navigation

Pulmotect Concludes Phase I Trial for Respiratory Infections Therapy
Preventing airborne infection: Pulmotect arms the lungs with extra immunity
Pulmotect Inc

3900 Essex Ln, Suite 575
Houston, TX 77027
Contact Us

© 2025
Pulmotect, Inc.